Table 1.
MDS Patient characteristics.
| Patient No. | PBF CD10 Ratio | WHO Dx | WPSS | Age/Sex | IPSS | Dysplastic Lineage(s) | Cytogenetics |
|---|---|---|---|---|---|---|---|
| 1 | 1.0 | RCMD | 3 | 76/F | 1 | Tri | Tri 8 |
| 2 | 1.5 | RCMD | 2 | 96/M | 0.5 | Tri | -20q |
| 3 | 1.7 | RCMD | 2 | 69/M | 0.5 | Tri | N |
| 4 | 1.7 | CMML | 3 | 86/M | 0 | Tri | N |
| 5 | 1.8 | RCMD-RS | 4 | 84/M | 1.5 | Bi (E&Me) | Mon 7 |
| 6 | 1.9 | RCMD | 2 | 73/M | 0.5 | Tri | N |
| 7 | 2.0 | RCMD | 1 | 85/M | 0 | Tri | N |
| 8 | 2.0 | RCMD | 2 | 80/M | 0.5 | Bi (E&Me) | N |
| 9 | 2.2 | CMML | 3 | 71/M | 0.5 | Tri | N |
| 10 | 2.2 | CMML | 4 | 71/M | 1.5 | Tri | -7q |
| RCMD | |||||||
| 11 | 2.5 | RCMD | 3 | 80/M | 1.5 | Bi: (E&Me) | Mon 7 |
| 12 | 2.6 | RCMD | 2 | 81/M | 0.5 | Tri | Tri 5 |
| 13 | 2.6 | RCMD | 1 | 47/F | 0.5 | Bi (E&Me) | N |
| 14 | 2.6 | RCMD | 2 | 64/M | 0.5 | Tri | N |
| 15 | 3 | RA | 1 | 72/M | 0.5 | Mono (E) | N |
| 16 | 3.1 | RA | 1 | 71/M | 1 | Mono | N |
| 17 | 3.1 | RCMD-RS | 2 | 89/M | 0.5 | Bi (E&Me) | N |
| 18 | 3.2 | RA | 1 | 78/M | 0.5 | Mono (Me) | -Y |
| 19 | 3.6 | RA | 1 | 77/M | 1 | Bi (Me & E) | -20q |
| 20 | 3.7 | RARS | 1 | 88/M | 0 | Mono+RS (Me) | -Y |
| 21 | 3.8 | RA | 1 | 58/M | 1 | Mono (Me) | N |
| 22 | 3.8 | RA | 1 | 67/M | 0.5 | Mono (E) | N |
| 23 | 4.0 | RCMD-RS | 2 | 77/M | 1.5 | Bi (E&Me) | N |
| 24 | 4.1 | RA | 1 | 88/M | 0 | Mono (Me) | -Y |
| 25 | 4.5 | RARS | 0 | 83/M | 1 | One+RS (E) | N |
| 26 | 4.7 | RARS | 1 | 82/M | 0.5 | Mono (My) | N |
| 27 | 4.7 | RA | 1 | 2 | Bi (My&E) | N | |
| 28 | 5.1 | RA | 1 | 75/M | 0 | Mono (E) | N |
| 29 | 5.3 | RA | 2 | 84/M | 0.5 | Mono (E) | Tri 15 |
PBF - peripheral blood flow cytometry; WHO - World Health Organization; WPSS - World Health Organization Prognostic Scoring System; IPSS - International Prognostic Scoring System; E - Erythroid, Me - Megakaryocytic, My - Myeloid; N - Negative; Tri - trisomy.